For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Response to speculation
This item is over 2 years old; some content may no longer be current
+Undoctored
Response to speculation
Wednesday 29 September 2021, 04:39 PM
Green Cross Health refers to speculation in the Australian media about its participation in a process to acquire Tamaki Health. Green Cross Health advises that it is working with Pacific Equity Partners (PEP) in that process, as the media speculates. The process is in its early stages.
The nature and terms of any transaction for the acquisition of Tamaki Health have yet to be determined. There is no certainty that Green Cross Health will be the successful party or that any transaction will be concluded.
Green Cross Health confirms it is in compliance with its continuous disclosure obligations.